BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv6.6.6//EN
X-ORIGINAL-URL:https://galencentre.org/
X-WR-CALNAME:Galen Centre
X-WR-CALDESC:A Malaysian health and social policy research organisation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-5291822d0636dc429e80e953c58b6a76@galencentre.org
DTSTART:20221122T160000Z
DTEND:20221124T160000Z
DTSTAMP:20220406T091200Z
CREATED:20220406
LAST-MODIFIED:20221115
PRIORITY:5
SEQUENCE:5
TRANSP:OPAQUE
SUMMARY:The 6th Health Economics Forum 2022
DESCRIPTION:Emerging Opportunities: Recalibrating the Value of Healthcare\n \n2022 heralds the return of the Health Economics Forum in Malaysia.\nThis year, it is an in-person-only event that encourages connecting and talking after two years of silence, online webinars and teleconferencing.\nIn a post-pandemic environment, the event has become even more pertinent when addressing the future of healthcare for all. \n \n \n\nThis year, the Health Economic Outcome Research (hEOR) and co-organisers, the Ministry of Health Malaysia and PhAMA (Pharmaceutical Association of Malaysia), look forward to facilitating dialogues in a “virtuous cycle” of debate on multiple topics.\nThe 6th Health Economics Forum 2022 will engage various stakeholders, experts, scholars and adept practitioners of Health Economics in crisis response, fundamentals of efficiency and sustainability by looking at Health Technology Assessments in strained systems.\nThe Forum will highlight innovation, access, value and affordability.\nThe 2022 edition features the legendary Professor Michael Drummond in a plenary session, “Value Assessment and Pursuing Innovation and Access in the Pandemic”. He will also share updates on CHEERS 2.0 – what is new in Health Economics evaluation guidelines.\nThe Forum also brings a senior professor of Health Economics at Ghent University, a former advisor to the Belgian Minister of Health, and one of Europe’s leading experts in health economics and Health Technology Assessment, Professor Lieven Annemans.\nThere’s an intense debate about the prices of innovative medicines. Are value-based prices the solution? Professor Annemans will share his perspective at the Forum.\n\n \nAfter two years, change is inevitable but necessary. So let us talk about this.\nJoin us from November 23-24 at Hilton Hotel Petaling Jaya!\n \n \n \n\nPartners\n \n\n \n\nAnnouncements\n \n\nFirst Announcement – With Tentative Agenda (Click to Download)\nSecond Announcement – With Tentative Agenda (Click to Download)\n\n \n\nPrevious editions of the Health Economic Forum\n \n\n2019: “An Efficient and Sustainable Healthcare System in Malaysia: The Challenges, Lessons and Future”. The 2019 Forum was the fifth installation of the very successful annual Forum event since 2013. The Forum has progressed and established itself as one of the most anticipated events on the local pharmaceutical industry calendar. The event featured some of the most prominent figures in the field of Health Economics, such as Emeritus Professor Adrian Towse from the Office of Health Economics (UK), Professor Mark Sculpher from University of York (UK), Professor Phua from Lee Kuan Yew School of Public Policy, National University of Singapore, and Professor SC Li from University of Newcastle (Australia). The Forum was supported by partners; Johnson & Johnson (M), Pfizer (M), Servier (M), Merck Sharp & Dohme(M), and IQVIA.\n\n \n\n2017: “The Role of Health Economics and Health Technology Assessment (HTA) in Establishing Value and Market Access for New Pharmaceuticals”. The workshop was conducted together with Professor Michael Drummond (University of York), Professor Kenneth Lee (Monash University Malaysia), Dr June Choon (Monash University Malaysia) and Dr David Wu (Agency for Care Effectiveness, Singapore). The event was supported by partners; Pfizer Sdn Bhd and Johnson and Johnson Sdn Bhd, and co-organizer, Pharmaceutical Association of Malaysia (PhAMA).\n\n \n\n2016: “Evidence-based Pricing and Access Schemes for New Pharmaceuticals: Future for Malaysia?” Many leading voices in the industry were invited – from both private and the government – to engage in a discourse on the challenges and implications of using evidence-based approach as a method of setting priorities for the utilization of health resources. The Forum featured Professor Michael Drummond, from the Centre for Health Economics, University of York as the keynote speaker.\n\n \n\n2015: “Access to Medicine by an Evidence-based Approach” aimed at providing an overview of government initiatives within the healthcare industry and the implications to healthcare providers. The forum highlighted lessons from other countries in using Health Technology Assessment (HTA) and how the implementation of HTA would work in the Malaysian healthcare system.\n\n\n\n2013: “Evidence-based Pricing and Access Schemes for New Pharmaceuticals: Future for Malaysia”\n\n \n\n2014: “Value of Medicines: Patient’s and Healthcare Professional’s Perspective”\n\n \n
URL:https://galencentre.org/eventsprimary/health-economics-forum-2022/
ORGANIZER;CN=Health Economics Outcomes Research:MAILTO:HEF2022@galencentre.org
CATEGORIES:hEOR
LOCATION:2, Jalan Barat, Pjs 52, 46200 Petaling Jaya, Selangor, Malaysia
ATTACH;FMTTYPE=image/png:https://i0.wp.com/galencentre.org/wp-content/uploads/2022/04/HEF2022masthead_BIG2.png?fit=2342%2C841&ssl=1
END:VEVENT
END:VCALENDAR